X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs PIRAMAL ENTERPRISES - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE PIRAMAL ENTERPRISES STRIDES PHARMA SCIENCE/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 50.9 7.7 661.0% View Chart
P/BV x 1.1 1.4 80.4% View Chart
Dividend Yield % 0.4 1.2 37.0%  

Financials

 STRIDES PHARMA SCIENCE   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
PIRAMAL ENTERPRISES
Mar-18
STRIDES PHARMA SCIENCE/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,1473,083 37.2%   
Low Rs6421,902 33.8%   
Sales per share (Unadj.) Rs317.2589.7 53.8%  
Earnings per share (Unadj.) Rs7.8284.0 2.8%  
Cash flow per share (Unadj.) Rs25.1310.5 8.1%  
Dividends per share (Unadj.) Rs2.0025.00 8.0%  
Dividend yield (eoy) %0.21.0 22.3%  
Book value per share (Unadj.) Rs274.31,467.0 18.7%  
Shares outstanding (eoy) m89.50180.27 49.6%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.84.2 66.7%   
Avg P/E ratio x114.08.8 1,299.4%  
P/CF ratio (eoy) x35.78.0 444.7%  
Price / Book Value ratio x3.31.7 192.0%  
Dividend payout %25.58.8 289.7%   
Avg Mkt Cap Rs m80,058449,332 17.8%   
No. of employees `0002.56.8 36.6%   
Total wages/salary Rs m4,34119,881 21.8%   
Avg. sales/employee Rs Th11,325.815,535.6 72.9%   
Avg. wages/employee Rs Th1,731.42,905.4 59.6%   
Avg. net profit/employee Rs Th280.17,482.5 3.7%   
INCOME DATA
Net Sales Rs m28,394106,310 26.7%  
Other income Rs m9412,595 36.2%   
Total revenues Rs m29,334108,906 26.9%   
Gross profit Rs m3,96551,599 7.7%  
Depreciation Rs m1,5404,773 32.3%   
Interest Rs m1,96229,783 6.6%   
Profit before tax Rs m1,40319,638 7.1%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97-28,764 -0.3%   
Profit after tax Rs m70251,203 1.4%  
Gross profit margin %14.048.5 28.8%  
Effective tax rate %6.9-146.5 -4.7%   
Net profit margin %2.548.2 5.1%  
BALANCE SHEET DATA
Current assets Rs m24,836118,154 21.0%   
Current liabilities Rs m18,993462,260 4.1%   
Net working cap to sales %20.6-323.7 -6.4%  
Current ratio x1.30.3 511.6%  
Inventory Days Days7127 267.0%  
Debtors Days Days11347 243.7%  
Net fixed assets Rs m34,289113,727 30.2%   
Share capital Rs m895361 248.3%   
"Free" reserves Rs m23,651264,093 9.0%   
Net worth Rs m24,546264,454 9.3%   
Long term debt Rs m15,513242,206 6.4%   
Total assets Rs m65,437726,834 9.0%  
Interest coverage x1.71.7 103.4%   
Debt to equity ratio x0.60.9 69.0%  
Sales to assets ratio x0.40.1 296.7%   
Return on assets %4.111.1 36.5%  
Return on equity %2.919.4 14.8%  
Return on capital %6.910.3 66.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69715,110 103.9%   
Fx outflow Rs m7354,298 17.1%   
Net fx Rs m14,96210,813 138.4%   
CASH FLOW
From Operations Rs m1,871-159,666 -1.2%  
From Investments Rs m5,826-17,677 -33.0%  
From Financial Activity Rs m-10,157186,503 -5.4%  
Net Cashflow Rs m-2,6159,364 -27.9%  

Share Holding

Indian Promoters % 27.7 52.9 52.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 4.0 945.0%  
FIIs % 8.6 26.6 32.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 16.5 157.0%  
Shareholders   56,241 93,274 60.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open on a Positive Note; Realty & Auto Stocks Lead(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 1.6%.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Dec 12, 2018 10:59 AM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - BIOCON LTD COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS